Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human T98G glioblastoma multiforme xenografts

Clinical Cancer Research

Volumn 7, Issue 3, 2001, Pages 634-640

  Teicher, B A ^a   Menon, K ^a   Alvarez, E ^a   Galbreath, E ^a   Shih, C ^a   Faul, M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARMUSTINE; CD31 ANTIGEN; COMPOUND 317615; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CELL SURVIVAL; CHRONOPHARMACOLOGY; CONTROLLED STUDY; DRUG EFFECT; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLIOBLASTOMA; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; ORGANIC CHEMICALS; PROTEIN KINASE C; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0034899448     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Neoplasms of the central nervous system
2. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models
3. Temozolomide for malignant brain tumors
4. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme
5. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies
6. Angiogenesis: New aspects relating to its initiation and control
7. Markers of tumor angiogenesis: Clinical applications in prognosis and anti-angiogenic therapy
8. What, if anything, is an angiogenic factor?
9. Regulation of tumor angiogenesis by organ-specific cytokines
10. Angiogenesis: A dynamic balance of stimulators and inhibitors
11. Effect of host microenvironment on the micro-circulation of human colon adenocarcinoma
12. Geometric resistance and microvascular network architecture of human colorectal carcinoma
13. The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors
14. A systems approach to cancer therapy
15. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications
16. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
17. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation
18. The phosphorylated 1169-tyrosine containing region of flt-I kinase (VEGFR-1) is a major binding site for PLCγ
19. VEGF receptor signaling in tumor angiogenesis
20. The role of protein kinase C in the regulation of cell growth and in signalling to the cell nucleus
21. Multiple biological responses activated by nuclear protein kinase C
22. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor I and elucidation of their importance in receptor activation and signal transduction
23. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C
24. Inhibitors of protein kinase C and related receptors for the lipophilic second-messenger sn-1,2-diacylglycerol
25. (S)-13-[(dimethylamino)methyl]-10,11,14,15tetrahydro-4,9,16,21-dimetheno-IH, 13H-dibenzo[e,k]pyrrolo[3,4h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase C Β
26. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCΒ inhibition with LY333531
27. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective Β-isoform-selective inhibitor
28. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC Β inhibitor
29. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis
30. The Jak/Stat signaling cascade
31. 1 arrest in vitro
32. Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-Β levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma
33. Influence of an antiangiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapy
34. Enzymatic rationale and preclinical support for a potent protein kinase CΒ inhibitor in cancer therapy
35. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma
36. Meningiomas: Role of vascular endothelial growth factor/ vascular permeability factor in angiogenesis and peritumoral edema
37. Expression and distribution of vascular endothelial growth factor protein in human brain tumors
38. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients
39. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: A review
40. Angiogenesis and brain edema in intracranial meningiomas: Influence of vascular endothelial growth factor
41. KDR activation in astrocytic neoplasms
42. New treatment strategies for malignant gliomas
43. Innovative therapies for pediatric brain tumors
44. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis
45. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma and ependymoma
46. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Antiangiogenic therapy
47. Expression of the angiogenic factor thymidine phosphorylase in human astrocytic tumors
48. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis
49. Therapeutic synergy of TNP-470 and ionizing radiation: Effects on tumor growth, vessel morphology and angiogenesis in human glioblastoma multiforme xenografts
50. Angiostatin suppresses malignant glioma growth in vivo
51. Combined effects of angiostatin and ionizing radiation in antitumor therapy
52. Critical derterminants of cancer metastasis: Rationale for therapy
53. Orthotopic models are necessary to predict therapy of transplantable tumors in mice
54. Modulation of tumor cell response to chemotherapy by the organ environment